Monday, August 21, 2017

Friday, August 18, 2017

Deutschland is marching to a faster pace. Look out, here comes the Master Race!


"In 2012, a 'white power' march in Charlotte, N.C., was met with counter-protesters dressed as clowns. They held signs reading 'wife power' and threw 'white flour' into the air."

Now here's a movement that needs to start quickly. "How to make fun of Nazis," in the New York Times.

Wednesday, August 16, 2017

"President Trump buoyed the white nationalist movement on Tuesday as no president has done in generations."

So says the New York Times, and for once, the Times and Klan leaders agree.

But perhaps the most alarming take on the events of this past week are in the New Yorker, where Robin Wright discusses the possibility of civil war with experts experienced in assessing such risks in other countries. She writes:

America’s stability is increasingly an undercurrent in political discourse. Earlier this year, I began a conversation with Keith Mines about America’s turmoil. Mines has spent his career—in the U.S. Army Special Forces, the United Nations, and now the State Department—navigating civil wars in other countries, including Afghanistan, Colombia, El Salvador, Iraq, Somalia, and Sudan. He returned to Washington after sixteen years to find conditions that he had seen nurture conflict abroad now visible at home. It haunts him. In March, Mines was one of several national-security experts whom Foreign Policy asked to evaluate the risks of a second civil war—with percentages. Mines concluded that the United States faces a sixty-per-cent chance of civil war over the next ten to fifteen years. Other experts’ predictions ranged from five per cent to ninety-five per cent. The sobering consensus was thirty-five per cent. And that was five months before Charlottesville.

Tuesday, August 15, 2017

A new kind of awareness campaign



Anyone familiar with modern drug marketing knows the role played by disease awareness campaigns. To sell Detrol, you sell overactive bladder. To sell Lyrica, you sell fibromyalgia. To sell Paxil, you sell social anxiety disorder. Raising awareness of a condition is a means of selling a treatment for it.

But Vanda Pharmaceuticals is trying something new. To sell its branded antipsychotic, Fanapt, Vanda is trying to raise awareness of a common antipsychotic side-effect called akasthisia -- the extreme restlessness and agitation that leads many patients to stop taking antipsychotics. Presumably, Vanda believes that Fanapt is less likely to cause akasthisia than its competitors. Commercials like this one lead viewers to Vanda's akasthisia awareness website, gotakasthisia.com.

You can get the details from Fierce Pharma.